We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 29, 2020

Outcomes in T2D Patients Following Addition of SGLT2 Inhibitors vs Sulfonylureas to GLP-IRA Therapy



Additional Info

Risk of Cardiovascular Outcomes in Type 2 Diabetes Patients Following Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-IRA Therapy
Circulation 2020 Dec 11;[EPub Ahead of Print], CV Dave, SC Kim, AB Goldfine, RJ Glynn, A Tong, E Patorno

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading